Testing a shorter tuberculosis treatment using high-dose rifampicin
Tests high-dose rifampicin for drug-sensitive lung tuberculosis in adults aged 19 to 85.
Plain-language title generated from the registry record
Registry title: Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 85 years old?
Source: NCT04485156, who can take part
Where in South Korea
- Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of MedicineSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT04485156
- Record updated
- 24 July 2020
- Original description
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.Read full original descriptionShow less
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Inclusion: Documented positivity by sputum Xpert MTB/RIF assay; Administration of current tuberculosis therapy (if any) for no more than 7 days (≤7) at the time of enrolment.
Exclusion: Any contraindications of drugs to be used; HIV positive; Cancer patient on anti-cancer chemotherapy; Chronic hepatitis, liver cirrhosis; Negative on Xpert MTB/RIF assay; Resistance to rifampicin as detected by an Xpert MTB/RIF assay; Known resistance to isoniazid, rifampicin, or pyrazinamide; Uncontrolled DM.